



Luxembourg, 18 December 2025

Environmental and Social Completion Sheet (ESCS)

Overview

Project Name:	OSE IMMUNOTHERAPEUTICS (EGFF) (COVID-19)
Project Number:	2019-0866
Country:	France
Project Description:	The Project concerned RDI investments in the Company's proprietary platform of innovative therapies for immuno-oncology and autoimmune diseases. The Company's pipeline included an immunotherapy that is in Phase III clinical stage for the treatment of lung cancer, as well as in Phase II clinical trial to pancreatic cancer, a humanised monoclonal antibody that is in preclinical stage for the treatment of various cancers, a humanized monoclonal antibody in Phase I clinical trial for the treatment of inflammatory autoimmune diseases and a prophylactic vaccine against SARS-CoV-2.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

No significant environmental issues were noted during the implementation of the Project. Due to the nature of the activity carried out by the Promoter and the number of clinical trials opened and in operation for the Pipeline development, the Project has generated positive societal impact considering the availability of additional therapy options for patients with serious or life-threatening diseases.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the Promoter that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.